Cannabinoid Receptor Antagonist
The discovery of the endogenous cannabinoid system led to the development of CB1 receptor antagonists. The first cannabinoid receptor "antagonist," rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and it has been shown to decrease food intake and regulate body-weight gain. The prevalence of obesity worldwide is increasing dramatically and has a great impact on public health. The lack of efficient and well-tolerated drugs to cure obesity has led to an increased interest in research and development of cannabinoid antagonists. Cannabidiol, a naturally occurring cannabinoid, is a non-competitive CB1/2 antagonist.
Read more about Cannabinoid Receptor Antagonist: History, Endocannabinoids and Their Signaling System, Mechanism of Action, Drug Design, Current Status, See Also
Famous quotes containing the word receptor:
“The disinterest [of my two great-aunts] in anything that had to do with high society was such that their sense of hearing ... put to rest its receptor organs and allowed them to suffer the true beginnings of atrophy.”
—Marcel Proust (1871–1922)